

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
30 May 2025 (30.05.2025)



(10) International Publication Number
WO 2025/111597 A1

(51) International Patent Classification:

A61K 31/395 (2006.01) A61K 31/33 (2006.01)
A61K 31/404 (2006.01)

LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2024/057185

Published:

— with international search report (Art. 21(3))

(22) International Filing Date:

22 November 2024 (22.11.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/601,854 22 November 2023 (22.11.2023) US

(71) Applicant: **GILGAMESH PHARMACEUTICALS, INC.** [US/US]; 113 University Place, Suite 1019, New York, New York 10023 (US).

(72) Inventors: **KRUEGEL, Andrew Carry**; c/o Gilgamesh Pharmaceuticals, Inc., 113 University Place, Suite 1019, New York, New York 10023 (US). **MAREK, Gerard Joseph**; c/o Gilgamesh Pharmaceuticals, Inc., 113 University Place, Suite 1019, New York, New York 10023 (US). **HUGHES, Zoe A.**; c/o Gilgamesh Pharmaceuticals, Inc., 113 University Place, Suite 1019, New York, New York 10023 (US).

(74) Agent: **GROLZ, Edward**; Scully, Scott, Murphy & Presser, 400 Garden City Plaza, Suite 300, Garden City, New York 11530 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,

(54) Title: A TREATMENT FOR PATIENTS WITH MOOD DISORDERS USING N-ETHYL-2-(5-FLUORO-1H-INDOL-3-YL)-N-METHYLETHAN-1-AMINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF

(57) Abstract: The present disclosure relates to a method of treating a patient having a mood disorder comprising administering to a subject in need thereof a pharmaceutical composition comprising a base compound comprising substantially pure N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine or a pharmaceutically acceptable salt thereof in a specific dosing regimen.

WO 2025/111597 A1